TP53 and large cell neuroendocrine carcinoma: About 60% of pulmonary LCNEC do not exhibit the SCLC molecular signature (TP53 and RB1 co-mutation) which might explain the large percentage of LCNEC patients who are platinum-refractory or rapidly progress on a platinum regimen (25, 37).